5 hours ago
1
Mohammed Haneefa Nizamudeen
BofA Securities has upgraded Vir Biotechnology (NASDAQ:VIR) to buy from neutral saying that the market is underestimating the company's phase 3 combo treatment for severe liver disease caused hepatitis delta virus.
The bank raised its price target to $14 from $12 (~215% upside based
English (US) ·